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The sera from 13 patients with malignant melanoma 
were evaluated for immune complexes by cryoprecipi-
tation and the 12 r.I Clq binding assay. Cryoprecipitates 
were identified in 12/13 patients (92%) and cryoimmu-
noglobulins in 7/13 patients (54%). Either cryoimmuno-
globulin or elevated Clq binding was identified in 8/ 13 
patients (62%). Incubation of normal monocytes with the 
resuspended cryoimmunoglobulin of 7 melanoma pa-
tients produced greater than 50% reduction in the ability 
of the monocytes to respond to chemotactic stimuli (p 
< .01). Similar inhibition was seen with cryoimmuno-
globulin from erythema multiforme patients, but not 
with 'medium alone, albumin, h eat aggregated albumin 
or heat aggregated-IgG in similar concentrations. No 
soluble factors produced in vitro could be demonstrated 
to produce this inhibition. Inhibition of monocyte func-
tion by immune complexes may be an important com-
ponent of impaired host response to malignant m ela-
noma, or alternatively may represent an important 
mechanism for the accumulation of monocytes at sites 
of inflammation, analogous to migration inhibition fac-
tor. 
The presence of immune complexes in t he sera of patients 
with mela noma and the importa nce of circulating factors in the 
control of th e immunologic response to maligna nt melanoma 
cells have been clearly established in both huma n a nd a nimal 
investigation. In several recent studies of large groups of cancer 
patients, approximately 50% of the patients with melanoma 
were found to have circulating immune complexes de tected 
either by Raji cell or Clq deviation or binding assays [1-3]. 
Both the percentage of p atients with circulating immune com-
plexes a nd the absolu te level of globulin involved in the com-
plexes we1·e higher among m ela noma patients than in most 
other cancer patients. In addition , the size of t he tumor load, 
the presence of m etastases, or the use of immunotherapy were 
correlated with an increase in the per cen tage and absolu te 
levels of immune complexes [1]. 
The H ellstroms a nd their associa tes first documented that 
the cell mediated immune response to melanoma tumor cells 
could be abrogated by antigen-a ntibody complexes from the 
sera of progressing melanom a patients [ 4-6]. S ubsequen t stud-
ies have shown that such " blocking" of tumor cytotoxicity can 
be caused by a nt ibody, ant igen, a ntigen-antibody complexes or 
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other so lu ble factors [7]. Other functiona l aspects oflymphocyte 
fun ction such as mitogen-induced blastogenesis [8] or mixed 
leukocyte response [9] have a lso been shown to be susceptible 
to inhibit ion by soluble factors in sera from melanoma patients. 
Defective monocyte chemotaxis has been demonstrated in a 
high proportion of m elanoma patients [10-11] and corrects with 
surgical removal of tumor, BCG immunotherapy or tumor 
vaccine [11]. S imilar depression or macrophage chemotaxis in 
an experimental mouse tumor system was found to be depen-
dent on a soluble fa ctor produced in vivo by t he neoplasm 
[12]. Thus, circulating factors and part icularly immune com-
plexes cause inhibition of various elements of th e host response 
and are found in a large percentage of melanom a patien ts. 
This study was designed to determine t he prevalence of 
cryoprecipitable immunoglobulins a nd proteins in t he sera of 
patien ts with melanoma, and to define the effect of these 
proteins in vitro on m onocyte chemotaxis. T his report will show 
that cryoprecipi table protein can be demonstrated in a very 
high proportion of melanoma patients a nd that resuspended 
cryoimmunoglobulin can inhibit m onocyte chemotaxis after 
short-term incubation in vitro. 
MATERIALS AND METHODS 
Patients 
Thi.rteen consecutive patients (5 women and 8 men), 26 to 75 yr of 
age wi th biopsy-proven malignant melanoma are studied. Patients were 
not selected as to stage, therapy, prognosis, or other parameters (Ta ble 
1) . Eleven patients were studied after removal of the primru·y lesion. A 
blood sample from each patient was allowed to clot at 37°C for 1 hr, 
and the serum was separated. T he serum was centrifuged repeatedly to 
assure the absence of red blood cells and l ml was frozen at -20°C and 
saved for the 1251 Clq binding assay. 
Cryoprec£pitates 
Cryoprecipi tates were obtained by refrigeration of the fresh serum 
at 4°C for 7 days. After separation from supernatant serum by centrif-
ugation at 4°C, cryoprecipi tates were washed at least 10 times with 50 
cc cold phosphate-buffered saline (PBS) pH 7.4. Serum proteins were 
shown to be absent in the concentrated final wash by immunodiffusion 
against antisera to human albumin and fibrin ogen (Hyland Laborato-
ries, Los Angeles, CA). Cryoprecipi tates were suspended in 0.5 cc of 
0.05 M barbi ta l buffer, pH 8.2. T he solubili ty of the cryoprecipitates in 
this buffer, though incomplete, was greater than in PBS [13]. A control 
group (62 patients) including 7 child1·en wi th acute rheumatic fever, 3 
adolescents wi th chronic asthma, 5 individuals with uncomplicated 
beta-hemolytic streptococcal pharyngitis, 6 children with cystic fibrosis 
(a ll of whom had a vaJ·iety of bacterial orga nisms isolated from the 
sputum) , 9 hospitalized patients with respiratory infections of undeter-
mined etiology, 1 patient with gram-negative epsis, 1 patient with 
S taph Aureus bacteremia, and 30 normal healthy adu lts [14] did not 
demonstrate measurable cryoprecipitates. 
Ch ara.cterizat£on of C!)•oprecip£/ a.tes 
Total cryoprotein was determined by the Folin-Lowry method. 
Cryoprecipitable IgG, IgA, and IgM were quantit.ated by radial immu-
nodiffusion on Kallestad low-level plates (Chaska, Minnesota). 
12
''! Clq B£nding A.ssay ( 12"! Clq BA) 
The 12''1 Clq binding assay for immune complexes was performed by 
the method of Zubler et al (1 5l Clq was isolated from normal human 
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TABLE I. Clinical Data 
Patient Age Sex Stage (Clark's level) Therapy prior to study Time since mel a- 'T'ime since removnl n ecurrence noma first noted of primary tumor 
1 75 F Ill DTIC 5 '1~ yr 4 '1.! yr + 
2 36 M l (4) None 6 mo 6 mo 
3 63 M I (3) BCG 3 mo 6 mo 
4 28 M III BCG, Leva misole 11 mo 5 mo + 
5 37 M III BCG, DTIC, CCNU 5 yr 5 yr +" 
6 28 M I (3) None 28'' 2 mo 
7 48 F II BCG ? 13 mo +" 
8 30 M III B CG, Laetrile 5 mo 4 mo + 
9 28 M I (3) None 28 yr 2 mo 
10 50 F II None 3 mo +" 
11 74 F I (4) None 5 y:r 1 mo 
12 26 M III Inadiation 3 mo + 
13 69 F lil BCG, DTIC, Levami- 17 yr 16 yr + 
" Patient now deceased . 
"Recurrence following immune complex studies. 
"Congenita l nevus. 
sole 
serum [ 16], radiolabeled with ' ~''I and reacted with the test sera [3,17]. 
Separation of fr ee from complex-bound 1251 Clq was achieved by selec-
t ive precipitat ion with polyethylene glycol (PEG) . Clq binding ac tivity 
(Clq BA) was expressed as the comparison of radioactive Clq precipi-
tated by PEG to that precipitated in a control tube by 20% trichloro-
acetic acid. R esults were expressed as the mean percent binding in 
duplicate assays. Clq BA was measured in over 100 apparently healthy, 
age and sex-matched subjects. The mean binding a nd standard devia-
tion were 8.8 a nd 2.7%, respectively. The mean plus 2 standa rd devia-
t ions was 14.2%. A Clq BA greater than 14.2 is considered abnormal. 
Monocyte Chemotaxis 
Monocyte chemotaxis was perform ed by modification of the method 
of Snyderman et al [18]. Venous blood from normal volunteers was 
collected in heparin (10 uni ts preservative-free heparin per ml) and 
layered over 9% Ficoll -Hypaqu e. After a 40 min centrifugation at 2000 
rpm the cushion of mononuclear cells was collected and washed x 3 in 
RPMI-1640 tissue culture media with 50 J.i penicillin and 50 J.J.g strep-
tomycin per milliliter. 'The percent monocytes was determined by 
neutral red pinocytosis after 5 min incubation [19]. In our laboratory 
this correlates well with nonspecific esterase staining for monocytes. 
Mononuclear cells were diluted to a concent ration of 3.2 x 10" 
monocytes per ml in RPMI-1640 with penicillin and streptomycin and 
were added to equal amounts of medium alone, medium containing 
albu min or medium conta ining resuspended cryoprecipi tate. Cryopre-
cipi tates were resuspended by incubation of the samples in barbital 
buffer at 37°C overnigh t One-tenth ml of t.he suspension was then 
diluted in 0.4 ml of ac idified RPMI-1640 so that the final pH of the 
mixture was 7.4, and this mixture was then added to a suspension of 
mononuclear cells conta ining 1.6 X lOr; monocytes in 0.5 cc. The 
concentration of cryoprotein in thj'! fina l incubation mixtures was 
between 44 and 233 J.J.g of protein per ml for the 7 melanoma patients 
studied. This was 3 to 5 times the concentration present in the patient's 
serum. Cryoprecipitates from patients with erythema mul tiforme, a 
benign reactive skin disease, were a lso used as a positive control in 
concentrates similar to those from the mela noma patients. Albumin at 
a concentration in the final incubation mixture of 160 /lg/ml was 
substituted for.cryoprotein as a protein cont rol. In the medium contro l 
barbital buffer was added in place of albumin or cryoprotein. Th ~ 
mononuclear cells a nd protein suspensions were incubated at 25°C for 
30 min a nd then 0.25 ml of the mix ture were added directly to each of 
3 chen)Otaxis chambers at a concentration of 4 X 10'' monocyles per 
chamber. Fresh human sera was activated with endotoxin (Lipopoly-
saccharide W, E . coli 0111:B4, Difco Lab, Detroit;, Michigan, USA) and 
diluted 10% in RPMI-1640 for use as attractant. The cells and aLLracLanl 
were partitioned by a sandwich of a 5 f' pore Nucleopore filter a nd a 
0.45 J.i pore filter (N ucleopore Corporation, P leasanton, California) 
separated by a 2 mm Teflon spacer. With this co mbination, cells passing 
through and detaching from t he 5 /L pore filter could be detected. The 
chambers were incubated for 90 min, and the fil ters were then fixed 
stained with hematoxylin and mounted for coun ting. Chemotaxis wa~ 
determined by counting the number of monocytes which have migrated 
completely through the 5 J.i filler in 20 oil power microgrid fie lds (XlOO). 
The cryoprote ins from the 7 of the 13 me lanoma patients with cryoim-
munoglobulins were studied in th is fash ion. Random movement con-
trols with medium in place of attractant established that in th is system 
random migration was minimal in compa rison to chemotax is. All assays 
were performed in triplicate and the results were expressed as mean 
and standaJ·d error of the mean (SEM) . 
Additiona l controls were performed using aggregated IgG, aggregated 
a lbumin or medium a lone in chemotactic experiments using the same 
technique described above. Aggregated IgG and albumi n were produced 
by heat aggregation of gamma globulin (Hyland, Cohn Fraction II) a nd 
albumin, as previously described [20,21]. Both aggregates at concentra-
tions of 400 or 2000 J.ig/ml were incubated with cells for 30 min at 25°C, 
and the cells were subsequently added to chemotactic chambers for 90 
min standard chemotactic assays. 
Soluble Inhibition of Chemotaxis 
To determine if a soluble factor capable of inhibi tion of cell migration 
was being produ ced in vitro during incubation of cryoprecipi tates a nd 
monocytes, standard mixtures of 1.6 X 10" monocytes were incubated 
with 100 J.ig of cryoprecipitate resuspended in 1 ml of a barbital buffer 
for 30 min at 37°C and for 90 min at 37°C. The supernatant was 
separated by centrifuga tion from the cell suspensions a nd held a t 4°C 
for 7 days to remove cryoprecipi tate. The cryoprecipita te-free suspen-
sion was then added directly to mononuclear cell suspension for 90 min 
chemotactic assays. Controls were established by adding medium with-
out cryoprecipitate to the original cell suspension and then collecting 
the supernatant as with the cryoprecipitate-containing samples. 
Additional supernatants collected from cryoglobulin-incubated mon-
ocytes a nd from medium-incubated control monocyles were prepared 
as above and added 1:1 to 10% Endotoxin activa ted serum in the lower 
well of chemotactic cha mbers to determine if a soluble attractant or 
chemotactic factor inactivator was produced by incubation of mono-
cytes and cryoprecipitates in vitro. 
Preparation of Artificial lmm.une Comp lexes 
R heumatoid factors were isolated from the serum of a patien t wi th 
rheumatoid arthritis and a latex fixation titer of 1:2560, as described by 
T ipton et a l (22]. Cohn frac tion II, dilu ted to 20 mg/ml in norma l 
saline, was aggregated by heating at 63°C for 15 min. The aggregated 
gamma globulin (AGG ) was mixed 1:3 with sod ium bicarbonate cou-
pling buffer (0.1 M, pH 8.3) wi th 0.5 M NaCl, and 14 ml of this solu tion 
(70 mg) was incubated overnight at 4°C with 2 gm of washed cyanogen 
bromide activated Sepharose 4B. The gel was washed with Tris buffer 
(0.05 M , pH 7.9), and then washed a lternately with borate buffered 
saline (pH 8.7) and acetate buffered saline (pH 4.0) . The AGG bound 
to Sepharose 4B was incubated ove'l'night at roo m temperature on a 
tilt table with 3 ml of the serum containing rheumatoid factors. The gel 
was washed free of protein with PBS (0.01 M , pH 7.2), and bound· 
rheumatoid factors were elu ted with 12 ml of glyc ine acetate buffer, pH 
3.6. T he rheumatoid factors were dialyzed aga inst PBS (0.01 M, pH 7.2) 
a nd concentrated in a n Amicon Concentrator to 3 ml. T he latex slide 
agglu t ination Liter of the purified rheumatoid factor was greater tha n 
1:160. 
Cryoprecipitates were formed by incubation of 0.5 ml of purified 
rheumatoid facto r (HF) with 0.5 ml of AGG a nd by incubation of0.5 ml 
o f' the serum conta ining RF with 0.5 ml of AGG for 48 hr at 4 °C. The 
precipitates formed were washed 3 Limes with cold PBS and were 
suspended in ·1 ml of ba rbital butTer, 0.05 M, pH 8.2. The protein content 
of each of these prepa rations was measured by the dye binding method 
[23]: Purified rheumatoid factor plus AGG-0.52 mg/ml; serum conta in -
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TABLE II. Laborat01y Findings 
Cryoimmunoglobu lins 
Patient mg/100 ml serum Cryoprot.ein mg/ 100 ml serum 
IgG lgA lgM 
1 .00 .00 .00 2.5 
2 .00 .00 .00 1.12 
3 .00 .00 .00 .30 
4 .00 .00 .07 .27 
5 .22 1.73 .07 . 82 
6 .29 .00 .50 4.35 
7 .31 .05 .80 3.1 
8 .36 .05 .19 3.15 
9 .00 .00 .11 3.66 
10 .00 .00 .00 0 
11 .00 .00 .00 1.50 
12 .40 .00 1.10 2.63 
13 .00 .00 .00 1.00 
N.D.-not done. 
ing RF plus AGG-3.18 mg/ml; aggregated gamma globulin-13.15 mg/ 
ml; and puritied RF-0.61 mg/ml. 
By radia l immunodiffusion the concentrations of immunoglobulins 
in the 4 preparations were as follows: (1) Purified rheumato id factor 
plus AGG-IgG 10.0 mg%, IgA 0.0 mg%, IgM 0.0 mg%; (2) rheumatoid 
factor serum plus AGG-IgG 24.0 mg%, lgA 10.5 mg%, lgM 4.2 mg%; (3) 
AGG-IgG 800.0 mg%, lgA 10.5 mg%, IgM 11.0 mg%; (4) pmified rheu-
matoid factor-IgG 21.0 mg%, IgA 9.1 mg%, IgM 34 .0 mg%. 
One hundred micrograms of protein from each of these 4 preparations 
were mixed with sufficient RPM! to give a volu me of 0.5 ml, and a 0.5 
ml suspension of peripheral blood mononuclear cells containing 1.6 X 
10° monocytes were added and incubated with slow agitation for 30 min 
at room temperature. After the incubation, monocyte chemotaxis wa 
performed in triplicate with 0.25 ml of the cell suspension per chemo-
taxis chamber. 
Demonstration of Ingestion of Cryoprecipitates by Monocytes 
Cryoprecipitate containing 80 /lg of IGM was resuspended in barbital 
buffer and added to 0.1 ml of 1:10 anti-human IgM conjugated to 
horseradish peroxidase (Dako, AccUJ·ate Chemical and Scientific Cor-
poration, Hicksville, NY) , and this mixture was then incubated with 1.6 
x 10n monocytes at 25°C for 30 min on a til t table. At the end of this 
time, the cell button was collected, stained for peroxidase activity and 
processed for electron microscopy. The photomicrographs were then 
examined for endogenous monocyte peroxisomes and for secondary 
lysosomes containing ingested amorphous protein and exogenous per-
oxidase label. 
S tatistics 
Significance of the chemotaxis resul ts was determined using a 2-
tailed Student's t-test. 
Chi-square analysis was used for comparison of the results with 
different assays for immune complexes. 
RESULTS 
Cryoprecipitates conta ining protein were detected in the sera 
of 12 of t he 13 melanoma patients (Ta ble II) . In 7 of these the 
cryoprecipitates wer e found to be immunoglobulins. IgM was 
detected in all 7 of these cryoprecipitates, l gG in 5, and lgA in 
3. The levels of cryoimmunoglobulins detected did not correlate 
with serum immunoglobulin levels . Sera from 4 of 11 patients 
tested showed a bnormal Clq binding. In all, 8 of 13 patients had 
e ither a bnormal Clq binding, cryoimmunoglobulins, or both. 
Six of these 8 patients h ave had evidence of r ecurrence of 
malignant melanoma (including 1 death) . Two of the 5 negative 
patients have had recurrences. However, one of these r ecur-_ 
rences (patient 10) fo llowed the immune complex studies, and 
the other (patient 13), in spite of numerous recurrences in one 
leg and in t he corresponding inguinal nodes, has remained alive 
for 17 yr after the onset of her first lesion (Table Ill). 
FiguTe 1 shows the effect on in vitro monocyte ch emotaxis 
after incubation cryoprotein from 7 melanoma patients, 
cryoprotein from 7 eryt hema multiforme patients, albumin and 
m edium. The numbers repr esent th e cells crossing the 5 fJ. filters 
12
''1 Clq Binding Serum immunoglobulins mg/ 100 ml serum (Normal < 14.2) 
G A M 
19. 1 1050 140 130 
10.1 800 60 60 
7.5 720 92 72 
9.9 880 770 52 
N.D . 820 115 85 
16.4 1800 115 850 
27.7 1200 120 100 
16.0 550 57 125 
6.1 2600 155 150 
9.7 N.D. N.D. N.D. 
7.9 1550 290 280 
6.0 1550 175 165 
8.6 1100 285 150 
TABLE III. Correlation of immune complexes with prognosis in 13 
patients with melanoma 
Evidence of in1mune com ~ Hecurrence No Hecu rrence Total plexes in sennn'' 
Present 6'' 2 8 
Absent 2" 3 5 
Total 8 5 13 
"Either elevated 125I Clq BA cryoimmunoglobulin. 
1
' Frequency of recurrence not significantly different between the 2 
groups (P = .2). 
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FIG. 1. Effect of cryoglobulins on monocyte chemotaxis. 
in 20 oil power fields (mean± SEM). S ignificant inhibition was 
seen with the cryoprotein fro m both th e melan oma and ery-
thema mul tifonne patients (p < .01). In con trast, the albumin-
contailling control produced no significant change from medium 
alone. Additional controls incubation of mononuclear cells with 
medium (n = 7), heat aggregated lgG (n = 8) o1· heat aggregated 
albumin (n = 8) produ ced no significant differences in monocyte 
chemotaxis in comparison to paired medium controls. T hus 
cryoprecipitates conta ining immune complexes from two bio-
logically different som ces, but not medium a lone, albumin alone 
or nonspecifically aggregated IgG or albumin produced signifi-
cant inhibit ion of monocyte ch emotaxis after short incubation . 
T a ble IV demonstrates the resul ts of experiments to deter-
mine whether th e inhibit ion of chemotaxis by cryoprecipitates 
was due to solu ble inhibi tors induced in vitro by the action of 
cryoprecipitate on mononuclear cells. Cryoprecipitate-free su-
pernatan ts were produced by incubation of mononuclear cells 
with cryoprecipitate or medium under the same conditions 
employed in the init ial chemotactic experiments. No significant 
inhibit ion of chemotaxis was seen when monocytes were incu-
bated with the supernatants from cryoprecipitate-incubated 
monocytes. When such supernatants are added to the attractant 
compartment instead of the cellula r compartment of Boyden 
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TABLE IV. T est ing fo r soluble inhibitors of chemotaxis produced in 
vitro: C1yoprecipitate-(ree supernatant:; incubated with mononuclear 
cells in standard chemotaxis 
Supernalanl Sou rce: 
Cells + cryoprecipi tate (n = 9) 
Cells alone (n = 6) 
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F IG. 2. Effect of artificial cryoprecipi tates on monocyte chemotaxis. 
chambers, t here was also no significant alteration in cell migra-
tion. These data indicate t hat no significant cell directed inhib-
itor or ch emotactic factor inhibitor, or, indeed, no potent che-
mattractants are produced in vitro to abolish t he experimental 
ch emattractant gradien t established or to inhibit the response 
of monocytes to that gradien·t. 
In Fig 2 th e effect of artificial cryoprecipitates on monocyte 
chemotaxis is contrasted to that of medium or purified rheu-
matoid factor alone. Significant inhibition of monocyte 
chemotaxis, similar in magnitude to that produced by the crude 
cryoprecipitate obtained from patient's sera, was seen only with 
a precipitate prepa1·ed from unpw-ified rheumatoid factor serum 
and aggregated IgG, but not from th e precipitate formed from 
purified rheumatoid factor and aggregated IgG, suggesting t hat 
other non-IgM serum factors may be critical in th e production 
of inhibition by cryoprecipitates. 
F inally, direct visualization by electron microscopy verified 
that resuspended cryoprecipitates, la belled with anti IgM-
bound to horseradish peroxidase .were phagocytized and fou nd 
in lysosomes containing la rge perox idase posit ive amorphous 
particles quite distinct from the endogenous peroxisomes found 
in cells incubated with medium or IgM-HRPO alone. 
DISCUSSION 
In this study we demonstrated cryoprecipita ble protein in 12 
of f3 patients with malignant melanoma (92%), and cryoim-
munoglobulins in 7 of these patients (54%). Complement-fixing 
compleJCes detected by Clq binding were present in 4 of 11 
patients studied (30%), and either elevated C lq BA or cryoim-
munoglobulin were present in 8 of 13 patients (62%). These 
resul ts are consistent with other studies in which approximately 
50% of melanoma patients had evidence of circulating immune 
complexes detected by either the Raji cell assay or Clq binding 
or deviation assays [1-3]. We a lso found a higher prevalence of 
markers of immu ne complexes in sera from patients who even-
tually developed recw-ren t disease, but the small numbers of 
patients involved and the short period of follow-up make the 
meaning of this fin ding difficult to interpret. Theoftlopoulos 
and his co-workers showed in a lru·ge number of melanoma 
patients that advanced disease was associated with increase in 
the percentage of patients with immune complexes and with 
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increases in th e absolute immunoglobulin concentrations in 
these complexes [1). Teshima et al [2] also detected ev idence of 
complexes in a large number of melanoma patients, and dem-
onstrated considerable day-to-day variability in their Clq devia -
tion assay and in t he serum Clq, C:, and CH "o measurements. 
The data presented h ere show that cryoprec ipitation is a lso a 
useful technique for identification of immune complexes in 
melanoma patients. 
The importance of vru·iations in immunologic reactivity to 
prognosis in malignant melanoma has been extensively studied 
in both human and animal models. Although melanoma com-
prises only 1 to 3% of all cancers, it accounts for 15% of the 
well-documented cases of spontaneous regTession in malignant 
tumors [24]. Patients with advanced disease sh ow profound, 
consistent defects in both humoral and cell-mediated immuni ty 
[7). In early disease it is difficult to determine any uniforl? 
defect in lymphocyte respo nsiveness, although the blastogemc 
response, mixed leukocyte reactivity or response to skin tests 
may be decreased in individual patients [25-26]. Patients with 
defects in direct cell mediated cytotoxicity against melanoma 
target cells appear to be at risk for more rapid progression of 
disease [27], but there is no consistent pattern in the measure 
of cellular cytotoxicity in different stages of disease [28]. Mel-
anoma patients produce antibody to a vru·iety of surface and 
cytoplasmic melanoma antigens, and certain specific antibody 
or anti-antibody responses correlate with disease progression 
[7]. Soluble inhibitors of cellular function such as immune 
complexes or rheumatoid factor [29] can be uniformly demon-
stTated in patients with progressing disease and become more 
prevalent as metastases occur [7]. The H ellstroms and their co-
workers initially demonstrated that " blocking" of cell -mediated 
cytotoxicity against melanoma cell line taTgets was caused by 
antigen-antibody complexes in serum of patients with progres-
sing disease, an effect which could be "unblocked" by sera from 
patients with regTessing melanoma [ 4]. Sera from melanoma 
patients also h ave "blocked" other lymphocyte functions, such 
as the mixed leukocyte reaction and mi togen-induced blasto-
genesis [8,9]. Tumor an tigen, antibody, immune complexes and 
other sera factors from melanoma and otheT cancer patients 
have all been correlated with progression of disease and block-
ing of specific immunologic fun ctions. 
Defective monocyte chemotaxis described in early melanoma 
patients appears to correct decrease of the t umor load or 
immunothera py [10-11]. Soluble inhibitors of monocyte ch em-
otaxis [12] and bactericidal function [30] have been described 
in the sera of animals bearing tumors. The observations re-
ported in this paper appear to link the immune complexes 
isolated and concentrated from the sera of melanoma patients 
with defective monocyte chemotaxis produced by incubation of 
t he cells with the resuspended immune complexes. Interest-
ingly, cryoglobulins from patients with a benign reactive skin 
disease, erythema multiforme, also inhibited monocyte 
chemotaxis in vitro but albumin or nonspecifically aggregated 
proteins or immunoglobulin in equivalent concentrations did 
not. The presence of inhibitors of cellular function in benign 
diseases does not mean that such factors are inconsequential in 
patients with malignant disease. Inhibi tion of migra tion of th e 
monocyte or macrophage may restrict t he availability of an 
important cell involved in processing tumor an tigen [31] and in 
several specific and nonspecific types of direct tumor cytotox-
icity [32-34]. The delicate balance between regression and 
progression in melanoma suggest that the inhibi t ion of mono-
cyte chemotaxis by immune complexes from th e sera of mela-
noma patients may have a profound effect on the availability of 
th e h ost to deal with malignancy. 
However, one might also hypothesize tha t immune com-
plexes, whatever the sou1·ce, are an important means of immo-
bilizing monocytes around tumors in situ or at tissue sites of 
inflammation, where monocytes can positively pa1ticipate in 
tissue destruction. Further investigation is necessary to deter-
mine if such a positive effect-similar to that attributed to MIF 
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(macrophage migration inhibi tion factor) - is important in vivo. 
Inhibition of neutrophil chemotaxis has previously been at-
tributed to cell directed inhibi tors and chemotactic factor in-
activations as well as to elevated monoclonal immunoglobulin, 
circulating immune complexes, or soluble IgA-containing com-
plexes [35-39]. Om experiments show that cryoprecipitable 
proteins containing immunoglobulin directly inhibit chemotaxis 
in vitro without the production of cell-directed inhibitors on 
chemotactic factor inactivators or by the production of endog-
enous attractants in vitro. The crude cryoprecipitates studied 
certainly contain other serum proteins other than immunoglob-
ulin, and our preliminary experiments using "artificia l" cry-
oprecipitates suggest that proteins other than immunoglobulin 
or antigen may be importan t in the inhibition of monocyte 
chemotaxis seen in vitro. 
In summary, markers of circulating immune complexes were 
identified in 54% of patients with malignant melanoma. Mono-
cytes incubated with resuspended cryoimmunoglobulins for 30 
min showed a 50% reduction in chemotactic response, whether 
the cryoproteins were from patients with malignant melanoma 
or benign disease. This demonstrates the value of appropriate 
selection of control patients with other diseases in defining 
nonspecific inhibitory effects of serum factors from patients 
with malignant disease. However, these findings do not mean 
that the inhibition in monocyte chemotaxis produced by mela-
noma cryoimmunoglobulins in vitro is insignificant in deter-
mining the eventual progression of the malignancy. These find-
ings also suggest that cryoprecipitable immune complexes con-
taining immunoglobulins or other serum protein may be impor-
tant in accumulating monocytes at sites of tissue inflammation 
where such precipitates may form, analogous to the effect of 
MIF in delayed type hypersensitivi ty. 
We thank Kathleen Wa nda and Rober ta Dustin for their excellent 
technical help and Sally Robben for preparation of the manuscrip t. 
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